Nevertheless, effects of MUC1-C on PD-L1 induction and immune invasion are widely seen in other cancers, including triple-negative breast cancer [61], and the MUC1-C inhibitor GO-203 has now completed a Phase I trial in patients with advanced solid tumours: patients are now being recruited for a Phase II trial of GO-203 in combination with decitabine for patients with AML (NCT02204085). Here, CD274 is linked to triple-negative breast carcinoma.